Literature DB >> 10201458

Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: a pilot study.

J Koerselman1, K G Pursnani, P Peghini, M A Mohiuddin, D Katzka, L M Akkermans, D O Castell.   

Abstract

OBJECTIVE: There is controversy in the literature on the effects of anticholinergic drugs on gastroesophageal reflux. Our aim was to study more extensively the effects of an oral anticholinergic drug on esophageal motility and gastroesophageal reflux in normal ambulant subjects under different circumstances: upright, supine, fed, and fasted state.
METHODS: Fifteen healthy subjects (seven men, eight women), mean age 34 yr (range, 22-61 yr) underwent randomized placebo-controlled 16-h evening and overnight ambulatory esophageal motility/pH study. After a 3-day loading dose of either oral dicyclomine (Dic) 20 mg four times daily or placebo (Pla), an ambulatory esophageal motility/pH study was performed while taking medication or placebo. Each study was analyzed for meal, first and second h postprandial, upright and supine periods, and first 2 h supine after bedtime snack.
RESULTS: The mean number of reflux episodes decreased with dicyclomine during the first h postprandial (Dic, 1.9 vs Pla, 2.5; p < 0.05). During the first 2 h supine, mean number of reflux episodes increased with dicyclomine (Dic, 1.4 vs Pla, 0.8; p < 0.09), as did mean percent time pH < 4 (Dic, 2.6 vs Pla, 0.5; p < 0.04), with an increase in clearance time (Dic, 0.9 vs Pla, 0.3; p < 0.05; in min). Mean peristaltic amplitude decreased with dicyclomine during the 2nd h postprandial (Dic, 48.8 vs Pla, 56.3; p < 0.04).
CONCLUSIONS: Oral dicyclomine caused a decrease in early postprandial upright reflux episodes, but also significantly increased the percent time pH < 4 during the first two h supine. Therefore, its effects are dependent on body position and fasted or fed state. Our results justify additional studies with oral anticholinergic agents in patients with gastroesophageal reflux disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201458     DOI: 10.1111/j.1572-0241.1999.988_k.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

Review 1.  The relevance of transient lower oesophageal sphincter relaxations in the pathophysiology and treatment of GORD.

Authors:  Neel Sharma; Simon H C Anderson
Journal:  Frontline Gastroenterol       Date:  2013-01-03

Review 2.  Neuro-regulation of lower esophageal sphincter function as treatment for gastroesophageal reflux disease.

Authors:  Anupender Singh Sidhu; George Triadafilopoulos
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

Review 3.  Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.

Authors:  Marcello Tonini; Roberto De Giorgio; Fabrizio De Ponti
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.

Authors:  A F Ciccaglione; L Marzio
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

5.  Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections.

Authors:  Morgan A Wambaugh; Steven T Denham; Magali Ayala; Brianna Brammer; Miekan A Stonhill; Jessica Cs Brown
Journal:  Elife       Date:  2020-05-05       Impact factor: 8.140

6.  Gastroesophageal Reflux Disease Is Not Associated With Jackhammer Esophagus: A Case-control Study.

Authors:  Matthew Woo; Andy Liu; Lynn Wilsack; Dorothy Li; Milli Gupta; Yasmin Nasser; Michelle Buresi; Michael Curley; Christopher N Andrews
Journal:  J Neurogastroenterol Motil       Date:  2020-04-30       Impact factor: 4.924

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.